ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Safety of testosterone therapy in men with prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 158777" data-attributes="member: 13851"><p><strong>Safety of testosterone therapy in men with prostate cancer </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Abraham Morgentaler </span></strong><span style="color: rgb(0, 0, 0)"><strong>& Monica Caliber </strong></span></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Abstract </strong></span></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Introduction: </strong></span><span style="color: rgb(26, 188, 156)"><strong>The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa.</strong></span> <span style="color: rgb(184, 49, 47)"><strong>Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has been shown to provide important symptomatic and general health benefits to men with testosterone deficiency (TD), including many men with PCa who may expect to live 30-50 years after diagnosis.</strong></span></p><p></p><p></p><p><strong>Areas covered:</strong> <span style="color: rgb(184, 49, 47)"><strong>This review outlines the historical underpinnings of the historical belief that TTh “fuels” PCa and the experimental and clinical studies that have radically altered this view, including description of the saturation model. </strong></span><span style="color: rgb(26, 188, 156)"><strong>The authors review studies of TTh in men with PCa following radical prostatectomy and radiation therapy, in men on active surveillance, and in men with advanced or metastatic PCa</strong></span>.</p><p></p><p></p><p><strong>Expert opinion:</strong> <span style="color: rgb(44, 130, 201)"><strong>TTh provides important symptomatic and overall health benefits for men with PCa who have TD. </strong></span><span style="color: rgb(250, 197, 28)"><strong>Although more safety studies are needed, TTh is a reasonable therapeutic option for men with low-risk PCa after surgery or radiation. Data in men on active surveillance are limited, but initial reports are reassuring. </strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 158777, member: 13851"] [B]Safety of testosterone therapy in men with prostate cancer [/B] [B][COLOR=rgb(184, 49, 47)]Abraham Morgentaler [/COLOR][/B][COLOR=rgb(0, 0, 0)][B]& Monica Caliber [/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]Abstract [/B][/COLOR] [COLOR=rgb(0, 0, 0)][B]Introduction: [/B][/COLOR][COLOR=rgb(26, 188, 156)][B]The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa.[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has been shown to provide important symptomatic and general health benefits to men with testosterone deficiency (TD), including many men with PCa who may expect to live 30-50 years after diagnosis.[/B][/COLOR] [B]Areas covered:[/B] [COLOR=rgb(184, 49, 47)][B]This review outlines the historical underpinnings of the historical belief that TTh “fuels” PCa and the experimental and clinical studies that have radically altered this view, including description of the saturation model. [/B][/COLOR][COLOR=rgb(26, 188, 156)][B]The authors review studies of TTh in men with PCa following radical prostatectomy and radiation therapy, in men on active surveillance, and in men with advanced or metastatic PCa[/B][/COLOR]. [B]Expert opinion:[/B] [COLOR=rgb(44, 130, 201)][B]TTh provides important symptomatic and overall health benefits for men with PCa who have TD. [/B][/COLOR][COLOR=rgb(250, 197, 28)][B]Although more safety studies are needed, TTh is a reasonable therapeutic option for men with low-risk PCa after surgery or radiation. Data in men on active surveillance are limited, but initial reports are reassuring. [/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Safety of testosterone therapy in men with prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top